The cognitive, affective motivational and clinical longitudinal determinants of apathy in schizophrenia.
Apathy
Longitudinal study
Negative symptoms
Partial least squares-path modeling
Journal
European archives of psychiatry and clinical neuroscience
ISSN: 1433-8491
Titre abrégé: Eur Arch Psychiatry Clin Neurosci
Pays: Germany
ID NLM: 9103030
Informations de publication
Date de publication:
Dec 2019
Dec 2019
Historique:
received:
10
01
2018
accepted:
22
05
2018
pubmed:
28
6
2018
medline:
22
4
2020
entrez:
28
6
2018
Statut:
ppublish
Résumé
Apathy is a frequent and debilitating condition with few treatment options available in schizophrenia patients. Despite evidence of its multidimensional structure, most of past studies have explored apathy through a categorical approach. The main objective of this study was to identify the cognitive, emotional, motivational, and clinical factors at baseline that best predicted the three subtypes of apathy dimensions at follow-up. In a longitudinal study, 137 participants diagnosed with schizophrenia underwent different assessments including clinical, motivational, affective and cognitive measurements, at 1-month (referred to as baseline) and 12-month follow-ups. Data were analyzed using partial least squares variance-based structural equation modeling. Three latent variables representing the three previously described domains of apathy reaching consensus in the literature were extracted from the Lille Apathy Rating Scale. Results showed that in addition to baseline apathy, positive symptoms, anticipatory pleasure and sensibility to punishment at baseline predicted cognitive apathy at follow-up. Likewise, both baseline apathy and sensibility to punishment predicted emotional apathy at follow-up. Finally, baseline anhedonia and episodic memory were the main variables the predicted behavioral apathy at follow-up. This is the first study to show specific associations between apathy subtypes and clinical and cognitive motivational dysfunction in individual with schizophrenia, indicating possible distinct underlying mechanisms to these demotivational symptoms. Treatment for apathy should address both types of processes. Importantly, our results demonstrate the interest of multidimensional approaches in the understanding of apathy in schizophrenia.
Identifiants
pubmed: 29948250
doi: 10.1007/s00406-018-0907-1
pii: 10.1007/s00406-018-0907-1
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
911-920Subventions
Organisme : Centre Hospitalier Régional Universitaire de Montpellier
ID : UF8641
Références
J Int Neuropsychol Soc. 2015 Jul;21(6):436-43
pubmed: 26135736
Biol Psychiatry. 1993 Oct 1;34(7):495-7
pubmed: 7903556
Am J Psychiatry. 2012 Apr;169(4):364-73
pubmed: 22407079
Mol Psychiatry. 2008 Mar;13(3):239, 267-76
pubmed: 17684497
Encephale. 2014 Jun;40(3):231-9
pubmed: 23958346
Int J Geriatr Psychiatry. 2011 Feb;26(2):158-65
pubmed: 20690145
Schizophr Res. 2014 Dec;160(1-3):186-92
pubmed: 25468186
Schizophr Bull. 2014 Mar;40 Suppl 2:S107-16
pubmed: 24375459
Schizophr Bull. 2015 Jul;41(4):892-9
pubmed: 25528757
Cereb Cortex. 2006 Jul;16(7):916-28
pubmed: 16207933
Clin Psychol Sci. 2017 Mar;5(2):226-238
pubmed: 28497008
Schizophr Bull. 2006 Apr;32(2):259-73
pubmed: 16221997
J Psychiatr Res. 2013 Jun;47(6):783-90
pubmed: 23453820
Neuropsychopharmacology. 2015 May;40(6):1539-48
pubmed: 25567425
Schizophr Res. 1996 May;19(2-3):205-12
pubmed: 8789919
Br J Psychiatry Suppl. 1989 Nov;(7):49-58
pubmed: 2695141
Behav Neurol. 2012;25(2):127-36
pubmed: 22425723
World Psychiatry. 2017 Feb;16(1):14-24
pubmed: 28127915
Schizophr Bull. 2016 May;42(3):642-51
pubmed: 26834026
Am J Psychiatry. 2003 Jan;160(1):13-23
pubmed: 12505794
BMC Med Res Methodol. 2010 Apr 30;10:37
pubmed: 20433707
Schizophr Res. 2012 Apr;136(1-3):19-24
pubmed: 22285655
Biol Psychiatry. 2013 Jul 15;74(2):130-6
pubmed: 23394903
Trends Psychiatry Psychother. 2016 Apr-Jun;38(2):96-9
pubmed: 27409135
Schizophr Res. 2014 Aug;157(1-3):278-84
pubmed: 24875172
J Neurol Neurosurg Psychiatry. 2006 May;77(5):579-84
pubmed: 16614016
Schizophr Bull. 2006 Apr;32(2):214-9
pubmed: 16481659
Schizophr Bull. 2011 Mar;37(2):300-5
pubmed: 20558531
Schizophr Res. 2014 Apr;154(1-3):89-92
pubmed: 24630140
Schizophr Bull. 1987;13(2):261-76
pubmed: 3616518
Neurosci Biobehav Rev. 2016 Oct;69:381-401
pubmed: 27527825
Psychiatry Res. 1991 Aug;38(2):143-62
pubmed: 1754629
Eur Psychiatry. 2009 Mar;24(2):98-104
pubmed: 19201579
Schizophr Bull. 2015 Mar;41(2):503-12
pubmed: 25053653
Am J Psychiatry. 2013 Feb;170(2):165-72
pubmed: 23377637
Br J Psychiatry Suppl. 1993 Dec;(22):39-44
pubmed: 8110442
Perspect Psychiatr Care. 2010 Jul;46(3):171-81
pubmed: 20591125
Schizophr Bull. 2009 Jul;35(4):798-806
pubmed: 18308717
Biol Psychiatry. 2009 Jun 15;65(12):1086-90
pubmed: 19246031
Acta Psychiatr Scand. 2014 Oct;130(4):290-9
pubmed: 24850369
Neurosci Biobehav Rev. 2013 Nov;37(9 Pt B):2149-65
pubmed: 23994273
Age (Dordr). 2016 Jun;38(3):55
pubmed: 27153818
Schizophr Bull. 1997;23(2):329-39
pubmed: 9165641
Schizophr Res. 2017 Aug;186:55-62
pubmed: 27293137
Am J Psychiatry. 2004 Jan;161(1):157-9
pubmed: 14702265
Mov Disord. 2013 Aug;28(9):1301-4
pubmed: 23712560
J Psychiatr Res. 2006 Oct;40(7):638-45
pubmed: 16643947
Schizophr Bull. 2009 May;35(3):549-62
pubmed: 19325164
J Clin Psychiatry. 2014;75 Suppl 1:3-7
pubmed: 24581452
Transl Psychiatry. 2016 May 03;6:e796
pubmed: 27138795
Schizophr Bull. 2017 Mar 1;43(2):344-354
pubmed: 27169465
Schizophr Res. 2011 Dec;133(1-3):193-8
pubmed: 21788116
Neuropsychol Rev. 2013 Sep;23(3):210-33
pubmed: 23921453
Neurology. 2013 Nov 5;81(19):1674-80
pubmed: 24107869
Eur Neuropsychopharmacol. 2014 May;24(5):725-36
pubmed: 24461724
Encephale. 2009 Jun;35(3):241-8
pubmed: 19540410